Clinical studies for newly diagnosed IDH1- or IDH2-mutated AML with IDH inhibitors used as monotherapy, in combination with intensive chemotherapy or with 5-azacitidine for unfit patients are running [21]. The gene discussed is IDH2; the disease is acute myeloid leukemia.